Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0UF9W
|
|||
| Former ID |
DAP001259
|
|||
| Drug Name |
Pegaptanib
|
|||
| Synonyms |
Macugen (TN); Pegaptanib Octasodium; Pegaptanib sodium; EYE 001; NX 1838; NX1838
Click to Show/Hide
|
|||
| Drug Type |
Aptamer
|
|||
| Indication | Neovascular age-related macular degeneration [ICD-11: 9B78.3Z; ICD-9: 362.5] | Approved | [1], [2], [3] | |
| Therapeutic Class |
Antiangiogenic Agents
|
|||
| Company |
Eyetech pharmaceuticals and Pfizer
|
|||
| Structure |
 |
Download2D MOL |
||
| Canonical SMILES |
COCCOC(=O)NCCCCC(C(=O)NCCCCCCCOP(=O)(C)O)NC(=O)OCCOC
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ADReCS Drug ID | BADD_D01690 ; BADD_D01691 | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Neuropilin-1 (NRP1) | Target Info | . | [3], [4] |
| KEGG Pathway | Axon guidance | |||
| HTLV-I infection | ||||
| Panther Pathway | Axon guidance mediated by semaphorins | |||
| Pathway Interaction Database | VEGF and VEGFR signaling network | |||
| Plexin-D1 Signaling | ||||
| VEGFR1 specific signals | ||||
| Reactome | Neurophilin interactions with VEGF and VEGFR | |||
| CRMPs in Sema3A signaling | ||||
| CHL1 interactions | ||||
| WikiPathways | miR-targeted genes in squamous cell - TarBase | |||
| miR-targeted genes in muscle cell - TarBase | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| miR-targeted genes in epithelium - TarBase | ||||
| Signaling by VEGF | ||||
| Semaphorin interactions | ||||
| L1CAM interactions | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6836). | |||
| REF 2 | Future pharmacological treatment options for nonexudative and exudative age-related macular degeneration. Expert Opin Emerg Drugs. 2005 Feb;10(1):119-35. | |||
| REF 3 | Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov. 2006 Feb;5(2):123-32. | |||
| REF 4 | Pegaptanib in the treatment of wet, age-related macular degeneration. Int J Nanomedicine. 2006;1(3):263-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.